| Followers | 17 |
| Posts | 1949 |
| Boards Moderated | 1 |
| Alias Born | 09/27/2020 |
Thursday, December 14, 2023 1:06:05 AM
Tollovid target site for 3CL protease inhibition is the site nature targets. Pfizer's Paxlovid targets a different site on the protein, which Dr. Arad has previously stated is likely more susceptible to viral mutations rendering it less effective. Paxlovid is based on her earlier research, while Tollovid is based on her latest research. I know I'm using the better product and thankful that Dr. Arad and Todos has made it available to me.
Recent TOMDF News
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
